When Eli Lilly snapped up Scorpion Therapeutics' PI3Kα program earlier this year, the deal allowed Scorpion to spin out a new ...

The latest clinical win follows a dual set of phase 3 and phase 2 results back in March. In that data drop, Mineralys reported that lorundrostat reduced systolic blood pressure in a late-stage study ...

Ventyx Biosciences has shared phase 2a data on a Parkinson’s disease prospect that has caught the eye of Sanofi. The readout shows the effect of VTX3232 on biomarkers, providing some of the data that ...

Gökhan Hotamışlıgil, M.D., Ph.D., has secured about $39 million from a Turkish investment group to support the next 10 years ...

China, already gaining speed in biotechnology, is looking to further accelerate novel drug development by reducing the time ...

Former CEO Anne Wojcicki has prevailed in the bankruptcy auction of 23andMe, its consumer and biopharma research businesses, ...

Eli Lilly is in talks to buy gene editing partner Verve Therapeutics for up to $1.3 billion, according to a report in ...

KalVista Pharmaceuticals has become the latest biotech to face delays to the FDA’s decision-making, as the agency apparently ...

A federal judge in Massachusetts has ruled that hundreds of grants terminated by the National Institutes of Health (NIH) must be restored immediately, the latest legal victory for groups challenging ...

NextCure has ramped up its antibody-drug conjugate (ADC) pivot, penning a $745 million deal for the ex-China rights to ...

Gilead is laying off 36 people as part of a rethink that saw the Big Pharma scrap plans to expand a biologics facility in ...

A South Korean biotech’s GLP-1 candidate has reduced liver fat in patients with metabolic dysfunction-associated ...